Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Moberg Pharma ABFRA:MB8 -0.60%36 Net-Net Working Capital is €0.42 as of Mar. 2026. GuruFocus rates FRA:MB8 with a GF Score™ of 36/100. The stock has 1 warning sign investors should review. Among 411 Drug Manufacturers companies, Moberg Pharma AB ranks better than 87.59% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Moberg Pharma AB's Net-Net Working Capital for the quarter that ended in Mar. 2026 was €0.42.
The industry rank for Moberg Pharma AB's Net-Net Working Capital or its related term are showing as below:
FRA:MB8's Price-to-Net-Net-Working-Capital is ranked better than 87.59% of 411
companies
in the Drug Manufacturers industry
Industry Median: 7.87
vs FRA:MB8: 2.19
Moberg Pharma AB (FRA:MB8) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Moberg Pharma AB Net-Net Working Capital Related Terms
Moberg Pharma AB Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Moberg Pharma AB's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:MB8 vs ZTS: Net-Net Working Capital Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moberg Pharma AB Price-to-Net-Net-Working-Capital vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Moberg Pharma AB's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of €0.42 mean?
Moberg Pharma AB (FRA:MB8) has a Net-Net Working Capital of €0.42 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Moberg Pharma AB According to the industry distribution chart, Moberg Pharma AB ranks #51 out of 411 companies in the Drug Manufacturers industry, placing it in the top 12.4%.
Is Moberg Pharma AB's Net-Net Working Capital too high?
Moberg Pharma AB's current Net-Net Working Capital is €0.42. Based on the distribution chart, Moberg Pharma AB ranks #51 out of 411 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Moberg Pharma AB has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Net-Net Working Capital compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Moberg Pharma AB ranks #51 out of 411 companies for Net-Net Working Capital. This places Moberg Pharma AB in the top 12% of its industry — outperforming the majority of peers. The industry median Net-Net Working Capital is 7.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Drug Manufacturers company?
The median Net-Net Working Capital among Drug Manufacturers companies is 7.87, based on 411 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Moberg Pharma AB For the Drug Manufacturers industry, the median Net-Net Working Capital is 7.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moberg Pharma AB's current Net-Net Working Capital is €0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current Net-Net Working Capital of €0.42. The current Net-Net Working Capital is €0.42. Moberg Pharma AB's overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current Net-Net Working Capital is €0.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
36GF Score
Get the complete analysis for FRA:MB8
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MB8 has been successfully added to your 
